

Bacterial meningitis

2000 to present:

Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningococcal disease. *Emerg Infect Dis* 2005;11(6):977-9.

1995-1999:

Schuchat A, Robinson KA, Wenger JD, Harrison LH, Farley MM, Reingold AL, Lefkowitz L, Perkins BA and the Active Surveillance Team. Bacterial meningitis in the United States in 1995. *N Engl J Med* 1997;337:970-6.

Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. *J Infect Dis* 1990;162:1316-23.

Group A Streptococcus

2000 to present:

O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold A, and Van Beneden C for the Active Bacterial Core Surveillance Team. The Epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications: United States, 2000-2004. *Clin Infect Dis* 2007; 45:853-61.

Thigpen MC, Richards CL, Lynfield R, Barrett NL, Harrison LH, Arnold KE, Reingold A, Bennett NM, Craig AS, Gershman K, Cieslak PR, Lewis P, Greene CM, Beall B, and Van Beneden CA for the Active Bacterial Core Surveillance/Emerging Infections Program Network. Invasive Group A Streptococcal Infection in Older Adults in Long-term Care Facilities and the Community, United States, 1998-2003. *Emerging Infectious Diseases* 2007;13:1852-59.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2006. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas06.pdf>

Johnson DR, Kaplan EL, VanGheem A, Facklam RR, Beall B. Characterization of group A streptococci (*Streptococcus pyogenes*): correlation of M-protein and *emm*-gene type with T-protein agglutination pattern and serum opacity factor. *J Med Microbiol.* 2006;55:157-64.

Persson J, Beall B, Linse S, Lindhal G. Extreme sequence divergence but conserved ligand-binding specificity in *Streptococcus pyogenes* M protein. *PLoS Pathog* 2006; 2(5):e47. Epub 2006 May 26.

Pletz MW, McGee L, Van Beneden CA, Petit S, Bardsley M, Barlow M, Klugman KP. The emergence of fluoroquinolone-resistance in invasive *Streptococcus pyogenes* isolates due to spontaneous mutation and horizontal gene transfer. *Antimicrob Agents Chemother.* 2006;50:943-8.

Sakota V, Fry AM, Lietman TM, Facklam RR, Li Z, Beall B. Genetically diverse group A streptococci from children in far-western Nepal share high genetic relatedness with isolates from other countries. *J Clin Microbiol.* 2006;44(6):2160-6.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2005. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas05.pdf>

Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. *Clin Diagn Lab Immunol.* 2005;12:833-6.

Factor SH, Levine OS, Harrison LH, Farley MM, McGeer A, Skoff T, Wright T, Schwartz B, Schuchat A. Risk Factors for Pediatric Invasive Group A Streptococcal Disease. *Emerg Infect Dis* 2005;11(7):1062-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2004. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas04.pdf>

Shulman ST, Tanz RR, Kabat K, Cederlund E, Patel D, Li Z, Sakota V, Dale JB, Beall B. Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. *Clin Infect Dis* 2004;39:325-32.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2003. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas03.pdf>

Espinosa LE, Li Z, Rodriguez RS, Facklam R, Beall B. M-protein gene type distribution within group A streptococcal clinical isolates recovered in Mexico during years 1991-2000: Overlap with type distribution within the United States. *J. Clin Microbiol* 2003;41:373-8.

Factor SH, Levine OS, Schwartz B, Harrison LH, Farley MM, McGeer A, et al. Invasive group A streptococcal disease: risk factors for adults. *Emerg Infect Dis* 2003;9(8):970-7.

Igwe EI, Shewmaker PL, Facklam RR, Farley MM, Van Beneden C, Beall B. Identification of superantigen genes *speM*, *ssa*, and *smeZ* in invasive strains of beta-hemolytic group C and G streptococci recovered from humans. *FEMS Microbiol Lett* 2003;229(2):259-64.

Jeng A, Sakota V, Li Z, Datta V, Beall B, Nizet V. Molecular genetic analysis of a group A *Streptococcus* operon encoding serum opacity factor and a novel fibronectin-binding protein, SfbX. *J Bacteriol* 2003;185(4):1208-17.

Li Z, Sakota V, Jackson D, Franklin AR, Beall B; Active Bacterial Core Surveillance/Emerging Infections Program Network. Array of M protein gene subtypes in 1064 recent invasive group A streptococcus isolates recovered from the active bacterial core surveillance. *J Infect Dis* 2003;188(10):1587-92.

Passaro DJ, Smith DS, Hett EC, Reingold AL, Daily P, Van Beneden CA, Vugia DJ. Invasive Group A Streptococcal Infections in the San Francisco Bay Area, 1989-1999. *Epidemiol Infect* 2003;129(3): 471-8.

Robinson KA, Rothrock G, Phan Q, Saylor B, Stefonek K, Van Beneden C, Levine OS. Active Bacterial Core Surveillance/Emerging Infections Program Network. Risk for severe group A streptococcal disease among patients' household contacts. *Emerg Infect Dis* 2003;9(4):443-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2002. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas02.pdf>

Chuang I, Van Beneden C, Beall B, Schuchat A and the ABCs/EIP Network. Population-based surveillance for postpartum invasive group A streptococcal infections, 1995-2000. *Clin Infect Dis* 2002;35:665-70.

Espinosa LE, Li Z, Rodriguez RS, Facklam R, Beall B. M protein gene type distribution within group A streptococcal clinical isolates recovered in Mexico during years 1991-2000: Overlap with type distribution within the United States. *J Clin Microbiol* 2002;41:373-8.

Facklam RF, Martin DR, Lovgren M, Johnson DR, Efstraiou A, Thompson TA, Gowan S, Kriz P, Tyrrell GJ, Kaplan E, and Beall B. Extension of the classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: *emm103* to *emm104*. *Clin Infect Dis* 2002;34:28-38.

Hu MC, Walls MA, Stroop S, Reddish M, Beall B, and Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. *Infect Immun* 2002;70:2171-77.

O'Brien K, Beall B, Barrett NL, Cieslak, Ringold A, Farley MM, Danila, Zell ER, Facklam R, Schwartz B, Schuchat A. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. *Clin Infect Dis* 2002;35:268-76.

The Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case-patients and among postpartum and post-surgical patients: Recommendations from the Centers for Disease Control and Prevention. *Clin Infect Dis* 2002;35:950-9.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2001. Available via the Internet: http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas01_provis.pdf

Stefonek KR, Maerz LL, Nielson MP, Besser RE, Cieslak PR. Group A streptococcal puerperal sepsis preceded by positive surveillance cultures. *Obstet Gynecol* 2001;98:846-48.

Beall B, Gherardi G, Lovgren M, Forwick B, Facklam R, and Tyrrell G. *emm* and *sof* gene sequence variation in relation to serological typing of opacity factor positive group A streptococci. *Microbiol* 2000;146:1195-1209.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas00.pdf>

Nizet V, Beall B, Bast DJ, Datta V, Kilburn L, Low DE, De Azavedo JC. Genetic locus for streptolysin S production by group A streptococcus. *Infect Immun* 2000;68(7):4245-54.

1995-1999:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas99.pdf>

Facklam R, Beall B, Efstratiou A, Fischetti V, Johnson D, Kaplan E, Kriz P, Lovgren M, Martin D, Schwartz B, Totolian A, Bessen D, Hollingshead S, Rubin F, Scott J, Tyrrell, G. Demonstration of *emm* typing and validation of provisional M types for group A streptococci. *Emerg Infect Dis* 1999;5:247-53.

Hoe NP, Nakashima K, Lukomski S, Grigsby D, Liu M, Kordari P, Dou SJ, Pan X, Vuopio-Varkila J, Salmenlinna S, McGeer A, Low DE, Schwartz B, Schuchat A, Naidich S, DeLorenzo D Yun-Xin F, Musser JM. Rapid selection of structural variants of group A streptococcus complement-inhibiting protein sustains and enlarges serotype M1 epidemic waves. *Nat Med* 1999;5:924-9.

York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in *Streptococcus pyogenes* isolates from the San Francisco Bay area of Northern California. *J Clin Microbiol* 1999;37(6):1727-31.

Beall B, Facklam R, Elliott JA, Franklin AR, Hoenes T, Jackson D, Laclaire L, Thompson T, Viswanathan R. Streptococcal *emm* types associated with T agglutination patterns and the use of conserved *emm* gene restriction fragment patterns for sub-typing group A streptococci. *J Med Microbiol* 1998;47:893-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas98.pdf>

The Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients. *JAMA* 1998;279:1206-10.

Zurawski CA, Bardsley M, Beall B, Elliott JA, Facklam RR, Schwartz B, Farley M. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. *Clin Infect Dis* 1998;27:150-7.

Beall B, Facklam R, Hoenes T, Schwartz B. A survey of *emm* gene sequences from systemic *Streptococcus pyogenes* infection isolates collected in San Francisco, California; Atlanta, Georgia; and Connecticut in 1994 and 1995. *J Clin Microbiol* 1997;35:1231-5.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas97.pdf>

Fiorentino TR, Beall B, Mshar P, Bessen DE. A genetic-based evaluation of principal tissue reservoir for group A streptococci isolated from normally sterile sites. *J Infect Dis* 1997;176:177-82.

Beall B, Facklam R, Thompson T. Sequencing *emm*-specific PCR products for routine and accurate typing of group A streptococci. *J Clin Microbiol* 1996;34:953-58.

Group B *Streptococcus*

2000 to present:

Centers for Disease Control and Prevention. Perinatal Group B Streptococcal Disease After Universal Screening Recommendations --- United States, 2003-2005. *Morb Mortal Wkly Rep* 2007;56(28):701-5.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2006. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs06.pdf>

Schrag SJ, Hadler J, Arnold KE, et al. Risk factors for invasive perinatal *Escherichia coli* sepsis in the era of widespread intrapartum antibiotic use. *Pediatrics* 2006;118(2):570-6.

Schrag SJ, Stoll BJ. Early-onset neonatal sepsis in the era of wide-spread intrapartum chemoprophylaxis. *Ped Infect Dis J* 2006;25(10):939-40.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2005. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs05.pdf>

Centers for Disease Control and Prevention. Early-Onset and Late-Onset Neonatal Group B Streptococcal Disease – United States, 1996-2004. *MMWR Morb Mortal Wkly Rep* 2005;54(47):1205-8.

Eisenberg E, Craig AS, Gautam S et al. Prevention Strategies for Perinatal Group B Streptococcal Disease: Beyond Screening. *Ped Infect Dis J* 2005;24:520-4.

Law, MR, Palomaki, G, Alfirevic, Z, Gilbert, R, Heath, P, McCartney, C, Reid, T and Schrag, S. The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. *J Med Screen* 2005;12:60-8.

Morin CA, White K, Schuchat A, Danila RN, Lynfield R. Perinatal group B streptococcal disease prevention, Minnesota. *Emerg Infect Dis* 2005;11(9):1467-9.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2004. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs04.pdf>

Centers for Disease Control and Prevention. Diminishing Racial Disparities in Early-Onset Neonatal Group B Streptococcal Disease, United States, 2000 - 2003. *MMWR Morb Mortal Wkly Rep* 2004; 53 (No.RR-23): 502-5.

Centers for Disease Control and Prevention. Laboratory Practices for Prenatal Group B Streptococcal Disease. MMWR Morb Mortal Wkly Rep 2004; 53 (No.RR-23): 506-9.

Balter S, Zell ER, O'Brien K, Roome A, Noga H, Thayu M, Schuchat A. Impact of intrapartum antibiotics on the care and evaluation of the newborn. *Pediatr Infect Dis* 2003;22:853-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2003. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs03.pdf>

Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. *Lancet Infect Dis* 2003;3(4):201-13.

Schrag SJ, Arnold KE, Mohle-Boetani JC, Lynfield R, Zell ER, Stefonek K, Noga H, Craig AS, Sanza LT, Smith G, Schuchat A. Prenatal Screening for Infectious Diseases and Opportunities for Prevention. *Obstet Gynecol* 2003;102:753-60.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2002. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs02.pdf>

Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. MMWR Morb Mortal Wkly Rep 2002;51(No.RR-11):1-22.

Hyde TB, Hilger TM, Reingold A, Farley MM, O'Brien KL, and Schuchat A for the Active Bacterial Core surveillance (ABCs) of the Emerging Infections Program Network. Trends in the incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. *Pediatrics* 2002;110(4):690-5.

Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig A, Harrison LH, Reingold A, Stefonek K, Smith G, Gamble M, Schuchat A. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. *New Engl J Med* 2002;347:233-9.

Schuchat A, Roome A, Zell ER, Linardos H, Zywicki S, O'Brien KL. Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections. *Maternal Child Health J* 2002;6(2):107-14.

Baltimore RS, Huie SM, Meek JI, Schuchat A, O'Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. *Pediatrics* 2001;108(5):1094-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2001. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs01.pdf>

Farley MM. Group B Streptococcal Infections in Nonpregnant Adults. *Clin Infect Dis* 2001;33:556-61.

Henning KJ, Hall EL, Dwyer DM, Billmann L, Schuchat A, Johnson JA, Harrison LH. Invasive group B streptococcal disease in Maryland nursing home residents. *J Infect Dis* 2001;183:1138-42.

Schuchat A. Group B streptococcal infections: from trials and tribulations to triumph and trepidation. *Clin Infect Dis* 2001;33:751-6.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs00.pdf>.

Centers for Disease Control and Prevention. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers- Connecticut and Minnesota. MMWR Morb Mortal Wkly Rep 2000; 49(11):228-32.

Centers for Disease Control and Prevention. Early-onset group B streptococcal disease, United States, 1998-1999. MMWR Morb Mortal Wkly Rep 2000;49(35):793-6.

Centers for Disease Control and Prevention. Hospital-based policies for prevention of perinatal group B streptococcal disease, United States 1999. MMWR Morb Mortal Wkly Rep 2000; 49(41):936-40.

Factor SH, Whitney CG, Zywicki SS, Schuchat A for the Active Bacterial Core Surveillance Team. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. Obstet Gynecol 2000;95:377-82.

Hager WD, Schuchat A, Gibbs R, Sweet R, Mead P, Larsen JW. Prevention of perinatal group B streptococcal infection: addressing current controversies. Obstet Gynecol 2000;96:141-5.

Schrag S, Whitney CG, Schuchat A. Neonatal group B streptococcal disease: How infection control teams can contribute to prevention efforts. Infect Control Hosp Epidemiol 2000:473-83.

Schrag SJ, Zywicki S, Farley M, Reingold A, Harrison L, Lefkowitz L, Hadler J, Danila R, Cieslak P, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20.

Schuchat A, Schrag S. Group B Streptococcus: from emerging infection to prevention success story. *In*: Scheld WM, Craig WA, Hughes JM. *Emerging Infections 4*. Washington, DC: American Society for Microbiology; 2000:107-20.

1995-1999:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs99.pdf>

Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal screening and reporting. MMWR Morb Mortal Wkly Rep 1999;48(20):426-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs98.pdf>

Centers for Disease Control and Prevention. Adoption of hospital policies for prevention of perinatal group B streptococcal disease – United States, 1997. MMWR Morb Mortal Wkly Rep 1998;47(32):665-70.

Harrison LH, Elliot JA, Libonati JP, Billmann L, Schuchat A, Dwyer DM, and the Maryland Bacterial Invasive Disease Surveillance Group. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. J Infect Dis 1998;177:998-1002.

Wessels MR, Kasper DL, Johnson KD, Harrison LH. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis 1998;178:569-72.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B *Streptococcus*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs97.pdf>

Centers for Disease Control and Prevention. Decreasing incidence of perinatal group B streptococcal disease -- United States, 1993-1995. MMWR Morb Mortal Wkly Rep 1997;46(21):473-7.

Rosenstein NE, Schuchat A, and the Neonatal Group B Streptococcal Disease Study Group. Opportunities for prevention of perinatal group B streptococcal disease: a multi-state surveillance analysis. Obstet Gynecol 1997;90:901-6.

Whitney C, Plikaytis BD, Gozansky W, Schuchat A, Neonatal group B streptococcal disease study group. Prevention practices for perinatal group B streptococcal disease: a multistate surveillance analysis. Obstet Gynecol 1997;89:28-32.

Blumberg HM, Stephens DS, Modansky M, Erwin M, Elliott J, Facklam RR, Schuchat A, Baughman W, Farley MM. Invasive group B streptococcal disease: the emergence of serotype V. *J Infect Dis* 1996;173:365-73.

Jackson L, Farley M, Schuchat A. Adult group B streptococcal disease. *Ann Int Med* 1996;125:152-3.

Schuchat A, Whitney C, Zangwill K. Prevention of perinatal group B streptococcal disease: a public health perspective. *MMWR Morb Mortal Wkly Rep* 1996;45 (RR-7):1-24.

Farley MM. Group B Streptococcal Infection in Older Patients: Spectrum of Disease and Management Strategies. *Drugs and Aging* 1995;6:293-300.

Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. *Ann Intern Med* 1995;123:421-7.

Jackson L, Hilsdon R, Farley M, Harrison L, Reingold A, Wenger JD, Schuchat A. Risk factors for group B streptococcal disease in adults. *Ann Intern Med* 1995;123:415-20.

1992 - 1994:

Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. *Pediatr Infect Dis J* 1994;13:623-9.

Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, Stephens DS. A population-based assessment of invasive disease due to group B streptococcus in nonpregnant adults. *N Engl J Med* 1993;328:1807-11.

Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal group B streptococcal infection: A population-based economic analysis. *JAMA* 1993;270:1442-8.

Zangwill KM, Schuchat A, Wenger JD, and the Group B Streptococcal Disease Study Group. Group B streptococcal disease in the United States: Report from a multistate active surveillance system. *MMWR Morb Mortal Wkly Rep* 1992; 41 [No. SS-6]:25-32.

Haemophilus influenzae

2000 to present:

Erwin AL, Sandstedt SA, Bonthuis PJ, Geelhood JL, Nelson KL, Unrath W CT, Diggle MA, Theodore MJ, Pleatman CR, Mothershed EA, Sacchi CT, Mayer LW, Gilsdorf JR, Smith AL. Analysis of Genetic Relatedness of *Haemophilus influenzae* Isolates by Multilocus Sequence Typing. *J Bacteriol* 2007; [*In press*].

Satola SW, Collins JT, Napier R, Farley MM. Capsule gene analysis of invasive *Haemophilus influenzae*: accuracy of serotyping and prevalence of IS1016 among nontypeable isolates. *J Clin Microbiol* 2007;45(10):3230-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2006. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib06.pdf>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2005. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib05.pdf>

Kapogiannis BG, Satola S, Keyserling HL, Farley MM. Invasive Infections with *H. influenzae* Serotype a Containing an IS *1016-bexA* Partial Deletion: Possible Association with Virulence. *Clin Infect Dis* 2005; 41:e97-103.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2004. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib04.pdf>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2003. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib03.pdf>

LaClaire LL, Tondella MLC, Beall DS, Nobel CA, Raghunathan PL, Rosenstein NE, Popovic T, and the ABCs Team Members. Identification of *Haemophilus influenzae* serotypes by standard slide agglutination serotyping and PCR-based capsule typing. J Clin Microbiol 2003;41:1:393-6.

Centers for Disease Control and Prevention. 2002. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2002. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib02.pdf>

Ohuabunwo C, Bath S, Bisgard K, Murphy T, Shutt K, Rosenstein N. Progress Toward Elimination of *Haemophilus influenzae* Type b Invasive Disease Among Infants and Children, United States, 1998--2000. MMWR Morb Mortal Wkly Rep 2002; 51(11); 234-7.

Raghunathan PL, LaClaire LL, Tondella ML, Beall DS, Noble CS, Rosenstein NE, Popovic T. Serotyping discrepancies in *Haemophilus influenzae* type b disease, United States, 1998—1999. MMWR Morb Mortal Wkly Rep 2002;51(32);706-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2001. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib01.pdf>.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib00.pdf>.

1995-1999:

Centers for Disease Control and Prevention. Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children – United States, 1990-1999. MMWR Morb Mortal Wkly Rep 1999;48(12);243-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib99.pdf>

Jafari HS, Adams WG, Robinson KA, Plikaytis BD, Wenger JD. Efficacy of *Haemophilus influenzae* type b conjugate vaccines and persistence of disease in disadvantaged populations. The *Haemophilus Influenzae* Study Group. Am J Public Health 1999;89:364-8.

Bisgard K, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. *Haemophilus influenzae* disease in the United States, 1994-1995: Near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998;4:229-37.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib98.pdf>.

Centers for Disease Control and Prevention. Progress Toward Elimination of *Haemophilus influenzae* Type b Disease Among Infants and Children -- United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998;47:993-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib97.pdf>

Centers for Disease Control and Prevention. Progress Toward Elimination of *Haemophilus influenzae* type b disease among infants and children -- United States, 1987-1995. MMWR Morb Mortal Wkly Rep 1996;45(42):901-6.

Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley MM, and the *H. Influenzae* study group. Invasive *Haemophilus influenzae* serotype f disease: Clinical and epidemiological characteristics in the Hib vaccine era. Clin Inf Dis 1996;22:1069-76.

Centers for Disease Control and Prevention. Progress toward elimination of *Haemophilus influenzae* Type b disease among infants and children—United States, 1993-1994. MMWR Morb Mortal Wkly Rep 1995;44(29):545-50.

1988 – 1994:

Centers for Disease Control and Prevention. Progress Toward elimination of *Haemophilus influenzae* type b disease among infants and children--United States, 1987-1993. MMWR 1994;43(8):144-8.

Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD. Decline of childhood *Haemophilus influenzae* Type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.

Farley MM, Stephens DS, Brachman PS Jr, Harvey RC, Smith JD, Wenger JD. Invasive *Haemophilus influenzae* Disease in Adults: Population-Based Surveillance. Ann Intern Med 1992; 116:806-12.

Farley MM, Stephens DS, Harvey RC, Sikes RK, Wenger JD, and the CDC Meningitis Surveillance Group. Incidence and Clinical Characteristics of Invasive *Haemophilus influenzae* in Adults. J Infect Dis 1992;165:S42-3.

Wenger JD, Pierce R, Deaver K, Franklin R, Bosley G, Pigott N, Broome CV. Invasive *Haemophilus influenzae* disease: A population-based evaluation of the role of capsular polysaccharide serotype. J Infect Dis 1992;165 [Suppl. 1]:S34-5.

Wenger JD, Pierce R, Deaver KA, Plikaytis BD, Facklam RR, Broome CV, and the *Haemophilus influenzae* Vaccine Efficacy Study Group. Efficacy of *Haemophilus influenzae* type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Lancet 1991;338:395-8.

Wenger JD, Harrison LH, Hightower A, Broome CV. Day care characteristics associated with *Haemophilus influenzae* disease. Am J Public Health 1990;80:1455-8.

Harrison LH, Broome CV, Hightower AW. *Haemophilus influenzae* type b polysaccharide vaccine: an efficacy study. Pediatrics 1989;84:255-61.

Harrison LH, Broome CV, Hightower AW, Hoppe CC, Makintubee S, Sitze SL, Taylor JA, Gaventa S, Wenger JD. A day care-based study of the efficacy of *Haemophilus b* polysaccharide vaccine. JAMA 1988;260:1413-8.

Methicillin-resistant *Staphylococcus aureus* (MRSA)

2000 to present:

Klevens MR, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK for the Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive Methicillin-Resistant *Staphylococcus aureus* Infections in the United States. JAMA 2007; 298(15):1763-71.

Klevens MR, Morrison MA, Fridkin SK, Reingold A, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati R, Townes JM, Craig AS, Fosheim G, McDougal LK, Tenover FC, for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Community-associate Methicillin-resistant *Staphylococcus aureus* and Healthcare Risk Factors. Emerg Infect Dis; 2006;12:1991-3.

Buck JM, Como-Sabetti K, Harriman KH, Danila RN, Boxrud DJ, Glennen A, Lynfield R. Community-associated Methicillin-resistant *Staphylococcus aureus*, Minnesota, 2000-2003. *Emerg Infect Dis*. 2005; 11(10):1532-8.

Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM for the Active Bacterial Core Surveillance Program of The Emerging Infections Program Network. Methicillin-resistant *Staphylococcus aureus* disease in three communities. *N Engl J Med* 2005;352:1436-44.

Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. Comparison of community and health care-associated methicillin-resistant *Staphylococcus aureus* infection. *JAMA* 2003;290:2976-84.

Morin C, Hadler JL. Population-based incidence and characteristics of community-onset *Staphylococcus aureus* infections with bacteremia in four metropolitan areas in Connecticut, 1998. *J Infect Dis* 2001;184:1029-34.

Neisseria meningitidis

2000 to present:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2006. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening06.pdf>

Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Stephens DS, and The Meningococcal Working Group. *Neisseria meningitidis* group B correlates of protection and assay standardization – International Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. *Vaccine* 2006;24:5093-107.

Harrison LH, Jolley KA, Shutt KA, Marsh JW, O'Leary M, Thomson Sanza L, Maiden MCJ. Antigenic shift and the incidence of meningococcal infection. *J Infect Dis* 2006;193(9):1266-74.

Harrison LH, Maiden MC. Reply to Tsang et al. *J Infect Dis* 2006;194:1792-3.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2005. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening05.pdf>

Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2005; 54(RR-7):1-21.

Dull P, Abdelwahab J, Sacchi C, Becker M, Noble C, Kaiser R, Mayer L, Whitney A, Schmink S, Dolan-Livengood J, Stephens DS, Ajello G, Creton M, Popovic T, Rosenstein N. Serogroup W-135 *Neisseria meningitidis* carriage among U.S. travelers to the 2001 Hajj. *J Infect Dis* 2005;191:33-9.

Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, Weyant R, Stephens DS, Perkins B, Rosenstein NA. Assessing the risk of laboratory-acquired meningococcal disease in the United States, 1996-2000. *J Clin Microbiol* 2005;24:4811-4.

Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. *Pediatrics* 2005;115(5):1220-32.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2004. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening04.pdf>

McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn A, Pacheco AGF, Shutt KA, Razeq J, Harrison LH. Epidemiologic trends and genotypes causing meningococcal disease, Maryland. *Emerg Infect Dis* 2004;10:451-6.

Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S, Mayer LW, Phelan M, Taylor TH, Bernhardt SA, Rosenstein NE, Popovic T. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of *Neisseria meningitidis*. *J Clin Microbiol* 2004; 42:320-8.

Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. *Ann Rev Med* 2004;55:333-53.

Zimmer S, Stephens DS. Meningococcal conjugate vaccine. *Expert Opin Pharmacother* 2004;4:855-63.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2003. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening03.pdf>

Dolan-Livengood JM, Miller YK, Kahler CM, Reeves M, Ajello G, Stephens DS. Genetic basis for nongroublable *Neisseria meningitidis*. *J Infect Dis* 2003;187:1616-28.

Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. *Pediatr Infect Dis J*, 2003;22:418-22.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2002. Available via the internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening02.pdf>

Kellerman S, McCombs K, Ray M, Farley MM, Rosenstein N, Popovic T, Blake P, Stephens DS, and the Georgia Emerging Infections Program. Genotype-specific carriage of *Neisseria meningitidis* in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. *J Infect Dis* 2002;186:40-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2001. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening01.pdf>

Finn R, Groves C, Coe M, Pass M, Harrison LH. A cluster of serogroup C meningococcal disease associated with attendance at a party. *South Med J* 2001;94(12):1192-4.

Harrison LH, Pass MA, Mendelsohn AB, Egri M, Pass M, Rosenstein NE, Razeq J, Roche JC. Invasive meningococcal disease in adolescents and young adults. *JAMA* 2001;286:694-9.

Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA and the Active Bacterial Core Surveillance (ABCs) Team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. *Vaccine* 2001;19(31):4566-75.

Popovic T, Schmink S, Rosenstein NA, Ajello GW, Reeves MW, Plikaytis B, Hunter SB, Ribot EM, Boxrud D, Tondella ML, Kim C, Noble C, Mothershed E, Besser J, Perkins BA. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by *Neisseria meningitidis* serogroup C. *J Clin Microbiol* 2001;39(1):75-85.

Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. *N Engl J Med* 2001;344:1378-88.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening00.pdf>.

Rosenstein NE, Stocker SA, Popovic T, Tenover FC, Perkins BA, and the Active Bacterial Core Surveillance Team. Antimicrobial resistance of *Neisseria meningitidis* in the United States, 1997. Clin Infect Dis 2000;30:212-3.

Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, Rosenstein NE, Perkins BA, Tondella MLC, Mayer LW. Diversity and prevalence of PorA types in *Neisseria meningitidis* serogroup B in the United States, 1992-1998. J Infect Dis 2000;182:1169-76.

Tondella M, Popovic T, Rosenstein N, Lake D, Carlone G, Perkins B. Distribution of *Neisseria meningitidis* serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000;38:3323-8.

1995-1999:

Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening99.pdf>

Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA. 1999;281(16):1493-7.

Harrison LH, Dwyer DM, Maples CT, Billmann L. The risk of meningococcal infection in college students. JAMA 1999;281:1906-10.

Rosenstein NE, Perkins BA, Stephens D, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL, and the Active Bacterial Core Surveillance Team. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180:1894-1901.

Yusuf HR, RoCHAT RW, Baughman WS, Gargiullo PM, Perkins BA, Brantley MD, Stephens DS. Maternal cigarette smoking and invasive meningococcal disease: a cohort study among young children in metropolitan Atlanta, 1989-1996. Am J Public Health 1999;89:712-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening98.pdf>

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening97.pdf>

Centers for Disease Control and Prevention. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46 (No. RR-5):1-10.

Centers for Disease Control and Prevention. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46 (No. RR-5):13-21.

Fischer M, Hedberg K, Cardosi P, Plikaytis BD, Hoesly FC, Steingart KR, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997;16:979-83.

Raymond NJ, Reeves M, Ajello G, Baughman W, Gheesling LL, Carlone GM, Wenger JD, Stephens DS. Molecular epidemiology of sporadic (endemic) serogroup C meningococcal disease. J Infect Dis 1997;176:1277-84.

Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, Stephens DS. Capsule switching of *Neisseria meningitidis*. Proc Natl Acad Sci 1997; 94:271-6.

Zangwill K, Schuchat A, Riedo FX, Pinner RW, Koo DT, Reeves MW, Wenger JD. School-based clusters of meningococcal disease in the United States: descriptive epidemiology and a case-control analysis. *JAMA* 1997;277:389-95.

Centers for Disease Control and Prevention. Serogroup Y meningococcal disease--Illinois, Connecticut, and selected areas, United States, 1989-1996. *MMWR Morb Mortal Wkly Rep* 1996;45:1010-13.

Centers for Disease Control and Prevention. Serogroup B Meningococcal Disease -- Oregon 1994. *MMWR Morb Mortal Wkly Rep* 1995;44:121-4.

Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. *Am J Public Health* 1995;85:843-5.

Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: An emerging threat. *JAMA* 1995;273:383-9.

Reeves MW, Perkins BA, Diermayer M, Wenger JD. Epidemic-associated *Neisseria meningitidis* detected by multilocus enzyme electrophoresis. *Emerg Infect Dis* 1995;1:53-4.

Stephens DS, Hajjeh RA, Baughman WS, Harvey CH, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. *Ann Intern Med* 1995;123:937-40.

1988 - 1994:

Jackson LA, Tenover FC, Baker C, Plikaytis BD, Reeves MW, Stocker SA, Weaver RE, Wenger JD, and the Meningococcal Disease Study Group. Prevalence of *Neisseria meningitidis* relatively resistant to penicillin in the United States, 1991. *J Infect Dis* 1994;169: 338-41.

Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected counties, United States, 1989-1991. *MMWR Morb Mortal Wkly Rep* 1993;42:21-30.

Pinner RW, Gellin BG, Bibb WF, Baker CN, Weaver R, Hunter SB, Waterman SH, Mocca LF, Frasch CE, Broome CV, and the Meningococcal Disease Study Group. Meningococcal disease in the United States - 1986. *J Infect Dis* 1991;164:368-74.

Streptococcus pneumoniae

2000 to present:

Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants after pneumococcal vaccination in the United States. *PLoS Pathog* 2007;3(11):e168.

Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG. ABCs/EIP. Incidence of Pneumococcal Disease Due to Non-Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the Era of Widespread PCV7 Vaccination, 1998-2004. *J Infect Dis* 2007;196(9):1346-54.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2006. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu06.pdf>

Barzilay EJ, O'Brien KL, Kwok YS, Hoekstra RM, Zell ER, Reid R, Santosham M, Whitney CG, Feikin DR. Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. *Vaccine* 2006;24(7):904-13.

Beall B, McEllistrem MC, Gertz RE, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG, and the ABCs Team. Pre- and post-vaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. *J Clin Microbiol* 2006;44(3):999-1017.

Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Li J, Campsmith M, Whitney CG, Schuchat A. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. *Ann Intern Med* 2006;144:1-9.

Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili, Roberson A, Zell ER, Whitney CG, Bennett NM for the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Preventability of Invasive Pneumococcal Disease and Assessment of Current Polysaccharide Vaccine Recommendations for Adults: United States, 2001-2003. *Clinical Infectious Diseases* 2006;43:141-50.

Kyaw MH, Greene CM, Schaffner W, Ray SM, Shapiro M, Barrett NL, Gershman K, Craig AS, Roberson A, Zell ER, Schuchat A, Bennett NM, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Adults with invasive pneumococcal disease: missed opportunities for vaccination. *Am J Prev Med.* 2006;31:286-92.

Kyaw MH, Lynfield R, Schaffner W, Craig AS, Halder J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant *Streptococcus pneumoniae*. *N Eng J Med* 2006; 354(14):1455-63.

Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Pelton SI. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. *Vaccine* 2006;24:2514-20.

Pai R, Gertz RE, Beall B. Sequential Multiplex PCR approach for determining capsular serotypes of *Streptococcus pneumoniae* isolates. *J Clin Microbiol.* 2006;44(1):124-31.

Pletz M, Shergill A, McGee L, Beall B, Whitney CG, Klugman KP. Active Bacterial Core Surveillance Team. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of *Streptococcus pneumoniae* in the United States. *Antimicrob Agents Chemother*; 2006; 50:1561-3.

Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, Hadler JL, Farley MM, Anderson BJ, Schaffner W. Invasive Pneumococcal Disease Among Infants Before and After Introduction of the Pneumococcal Conjugate Vaccine. *JAMA* 2006;295(14):1668-74.

Ray GT, Whitney CG, Fireman BH, Ciruryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. *Pediatr Infect Dis J.* 2006;25(6):494-501.

Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. *Lancet.* 2006;368(9546):1495-502.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2005. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu05.pdf>

Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998-2003. *MMWR Morb Mortal Wkly Rep* 2005;54(36): 893-7.

Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CG, ABCs/EIP. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. *Clin Infect Dis* 2005;41(4):481-7.

Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnoon K, Holford TR, Schuchat A. Declining incidence of invasive *Streptococcus pneumoniae* infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. *J Infect Dis* 2005;191(12):2038-45.

Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. *J Infect Dis* 2005;192(3):377-86.

Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG, for the ABCs Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. *JAMA* 2005;294(16):2043-51.

Lipsitch, M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? *PLoS Med* 2005; 2(1): e15.

McEllistrem MC, Adams JM, Shutt K, Sanza LT, Facklam RR, Whitney CG, Jorgensen JH, Harrison LH. Erythromycin-nonsusceptible *Streptococcus pneumoniae* in children, 1999-2001. *Emerg Infect Dis* 2005;11(6):969-72.

Pai R, Gertz RE, Whitney CG, Beall B. Clonal association between *Streptococcus pneumoniae* serotype 23A, circulating within the United States, and an internationally dispersed clone of serotype 23F. *J Clin Microbiol* 2005;43(11):5440-4.

Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, Active Bacterial Core Surveillance Team. Post-vaccine genetic structure of *Streptococcus pneumoniae* serotype 19A from children in the United States. *J Infect Dis* 2005;192(11):1988-95.

Pai R, Limor J, Beall B. Use of pyrosequencing to differentiate *Streptococcus pneumoniae* serotypes 6A and 6B. *J Clin Microbiol* 2005;43(9):4820-2.

Pettigrew MM, Fennie KP. Genomic subtraction followed by dot blot screening of *Streptococcus pneumoniae* clinical and carriage isolates identifies genetic differences associated with strains that cause otitis media. *Infect Immun* 2005;73:2805-11.

Pletz MW, McGee L, Beall B, Whitney CG, Klugman KP. Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive *Streptococcus pneumoniae* isolates in the United States. *Antimicrob Agents Chemother* 2005;49(2):779-80.

Stephens DS, Zughaiier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM and the Georgia Emerging Infections Program. Incidence of macrolide resistance in *Streptococcus pneumoniae* after introduction of the pneumococcal conjugate vaccine: population-based assessment. *Lancet* 2005;365:855-63.

Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, Schaffner W, Craig AS, Griffin MR. Asthma is an independent risk factor for invasive pneumococcal disease. *N Engl J Med* 2005;352:2082-90.

Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. *Antimicrob Agents Chemother* 2005;49(8): 3554-7.

Yu J, Lin J, Benjamin WH Jr, Waites KB, Lee CH, Nahm MH. Rapid multiplex assay for serotyping pneumococci with monoclonal and polyclonal antibodies. *J Clin Microbiol* 2005;43:156-62.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2004. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu04.pdf>

Centers for Disease Control and Prevention. Effect of New Susceptibility Breakpoints on Reporting of Resistance in *Streptococcus pneumoniae* --- United States, 2003. MMWR Morb Mortal Wkly Rep 2004;53(07):152-4.

Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, Cieslak PR, Hadler J, Farley MM, Facklam RR, Zell ER, Whitney CG. ABCs/EIP Impact of childhood vaccination on racial disparities in invasive *Streptococcus pneumoniae* infections. JAMA 2004;291(18):2197-203.

Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG. Comparative activities of Cethromycin and Telithromycin against recent North American isolates of *Streptococcus pneumoniae*. Antimicrob Agents Chemother 2004;48:605-7.

Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG. Detection of resistance to Gatifloxacin and Moxifloxacin in *Streptococcus pneumoniae* with the VITEK 2 instrument. J Clin Microbiol 2004;42:5928-30.

Klugman KP. Vaccination: A Novel Approach to Reduce Antibiotic Resistance. Editorial Commentary. Clin Infect Dis 2004;39(5):649.

Mavroidi A, Godoy D, Aanensen DM, Robinsom DA, Hollingshead SK, Spratt BG. Evolutionary genetics of the capsular locus of serogroup 6 pneumococci. J Bacteriol 2004;186(24):8181-92 .

McEllistrem MC, Noller AC, Visweswaran S, Adams JM, Harrison LH. Serotype 14 variants of the France 9V³ clone from Baltimore, Maryland, can be differentiated by the *cpsB* gene. J Clin Microbiol 2004;42:250-6.

Pletz MW, McGee L, Jorgensen J, Beall B, Facklam RR, Whitney CG, Klugman KP. Levofloxacin-Resistant Invasive *Streptococcus pneumoniae* in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine. Antimicrob Agents Chemother 2004;48(9):3491-7.

Schrag, SJ, McGee, L, Whitney, CG, Beall, B., Craig, AS, Choate, ME, Jorgensen, JH, Facklam, RR, Klugman, KP and the ABCs Team. Emergence of *Streptococcus pneumoniae* with Very-High-Level Resistance to Penicillin. Antimicrob Agents Chemother 2004; 48:3016–23.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR. Reduction in High Rates of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in Tennessee after Introduction of the Pneumococcal Conjugate Vaccine. Clin Infect Dis 2004;39(5):641-8.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KH, Griffin MR. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J 2004;23:726-31.

Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong W, Wang W. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J. Pediatr 2003;143(4):438-44.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2003. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneum03.pdf>

Dowell SF, Whitney CG, Wright C, Rose CE, and Schuchat A. Seasonal Patterns of Invasive Pneumococcal Disease. Emerg Infect Dis 2003;9(5):573-9.

Fry AM, Facklam RR, Whitney CG, Plikaytis BD and Schuchat A. Multistate evaluation of invasive pneumococcal diseases in adults with HIV infection: serotype and antimicrobial resistance patterns in the United States. *J Infect Dis* 2003;188(5):643-52.

Gertz RE, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA, Facklam RR, Besser JM, Harrison LH, Whitney CG, Beall B. Clonal Distribution of Invasive Pneumococcal Isolates from Children and Selected Adults in the United States Prior to 7-Valent Conjugate Vaccine Introduction. *J Clin Microbiol* 2003;41(9):4194-216.

King MD, Whitney CG, Parekh FM,, and Farley MM. Recurrent Invasive Pneumococcal Disease: A Population-Based Assessment. *Clin Infect Dis* 2003;37:1029-36.

Kupronis BA, Richards JC, Whitney CG, Team ABCS: Invasive pneumococcal disease among older adults residing in long-term care facilities and in the community. *J Am Geriatr Soc* 2003;51(11):1520-25.

McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, Samore MH, Lipsitch M. Geographic Diversity and Temporal Trends of Antimicrobial Resistance in *Streptococcus pneumoniae* in the United States. *Nat Med* 2003;9(4):424-30.

Restrepo MI, Velez JA, Mcelmeel ML, Whitney CG, Jorgensen JH. Activity of daptomycin against recent North American isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2003;47(9):2974-7.

Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG: Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of co morbid conditions and race. *Ann Intern Med* 2003; 138(12): 960-8.

Thomas DM, Ray SM, Morton FJ, Shevlin JD, Offutt G, Whitney C, Jacobson T. Patient education strategies to improve pneumococcal vaccination rates: a randomized trial. *J Invest Med* 2003;51(3):141-8.

Van Beneden CA, Lexau C, Baughman W, Barnes B, Bennett N, Cassidy PM, et al. Aggregated Antibiograms and Monitoring of Drug-resistant *Streptococcus pneumoniae*. *Emerg Infect Dis* 2003;9(9):1089-95.

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *New Engl J Med* 2003;348(18):1737-46.

Albanese BA, Roche JC, Pass M, Whitney CG, McEllistrem MC, Harrison LH. Geographic, demographic, and seasonal differences in penicillin-resistant *Streptococcus pneumoniae* in Baltimore. *Clin Infect Dis* 2002;34(1):15-21.

Beall B, McEllistrem MC, Gertz RE Jr, Boxrud DJ, Besser JM, Harrison LH, Jorgensen JH and Whitney CG, for the Active Bacterial Core Surveillance/ Emerging Infections Program Network. Emergence of a novel penicillin resistant clone of serotype 35B *Streptococcus pneumoniae* in the United States. *J Infect Dis* 2002;186:118-22

Braum SE, Crawford SA, McEneel ML, Whitney CG, Jorgensen JH. Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2002;46(9):3094-5.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2002. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu02.pdf>

Centers for Disease Control and Prevention. Assessment of Susceptibility Testing Practices for *Streptococcus pneumoniae* – United States, February 2000. *MMWR Morb Mortal Wkly Rep* 2002;51(18):392-4.

Fry AM, Zell ER, Schuchat A, Butler JC Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. *Vaccine* 2002;21:303-11.

McEllistrem MC, Mendelsohn AB, Elliott JA, Whitney CG, Albanese BA, Harrison LH. Distribution of penicillin-nonsusceptible pneumococcal clones in the Baltimore metropolitan area and variables associated with drug resistance. *Clin Infect Dis* 2002;34(5):704-7

McEllistrem MC, Mendelsohn AB, Pass MA, Elliott JA, Whitney CG, Kolano JA, Harrison LH. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. *J Infect Dis* 2002;185:1364-8.

Morita JY, Zell ER, Danila R, Farley MM, Hadler J, Harrison LH, Lefkowitz L, Reingold A, Kupronis BA, Schuchat A, Whitney CG. Association between antimicrobial resistance among pneumococcal isolates and burden of invasive pneumococcal disease in the community. *Clin Infect Dis* 2002;35:420-7.

Schrag SJ, Zell E, Schuchat A, Whitney CG. Evaluation of sentinel surveillance for drug-resistant *Streptococcus pneumoniae*. *Emerg Inf Dis* 2002;8(5):496-502.

Shelvin JD, Summers-Bean C, Thomas D, Whitney CG, Todd D, Ray SM. A symptomatic approach for increasing pneumococcal vaccination rates at an inner-city hospital. *Am J Prev Med* 2002;22(2):92-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2001. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu01.pdf>

Centers for Disease Control and Prevention. Resistance of *Streptococcus pneumoniae* to Fluoroquinolones --- United States, 1995--1999. *MMWR Morb Mortal Wkly Rep* 2001;50(37):800-4.

Ehresmann KR, Ramesh A, Como-Sabetti K, Peterson DC, Whitney CG, Moore KA. Factors associated with self-reported pneumococcal immunization among adults 65 years of age or older in the Minneapolis-St. Paul metropolitan area. *Prev Med* 2001;32(5):409-15.

Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Barrett NL, Schaffner W, Cieslak PR, Maupin PS, Zell ER, Jorgensen JH, Facklam RR, Whitney CG. Active Bacterial Core Surveillance/Emerging Infections Program Network. Macrolide resistance among invasive *Streptococcus pneumoniae* isolates. *JAMA* 2001;286(15):1857-62.

Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley M, Jorgensen JH, Phelan M, Facklam RR, Cetron MS, Breiman RF, Kolczak M, Schuchat A. Clinical outcomes of invasive pneumonia caused by *Streptococcus pneumoniae* in the era of antibiotic resistance. *Clin Infect Dis* 2001;33:797-805.

Robinson K, Baughman W, Rothrock G, Barrett N, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell E, Schuchat A, Whitney C. Epidemiology of *Streptococcus pneumoniae* infections in the U.S., 1995-1998 – Opportunities for prevention in the conjugate vaccine era. *JAMA* 2001;285:1729-35.

Beall B, Gherardi G, Facklam R, and Hollingshead S. Pneumococcal *psp A* sequence types of prevalent multi-resistant strains in the United States and of internationally disseminated pneumococcal clones. *J Clin Microbiol* 2000;38:3663-9.

Breiman RF, Keller DW, Phelan M, Sniadack D, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold A. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. *Arch Intern Med*. 2000;160:2633-8.

Centers for Disease Control and Prevention. 2000. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu00.pdf>

Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2000;49(No.RR-9):1-35.

Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. *Am J Public Health* 2000;90:223-9.

Fiore AE, Moroney JF, Farley MM, Harrison LH, Patterson JE, Jorgensen M, Kolczak MS, Breiman RF, Schuchat A. Clinical outcomes of meningitis caused by *Streptococcus pneumoniae* in the era of antibiotic resistance. *Clin Infect Dis* 2000;30:71-7.

Gay K, Baughman W, Miller Y, Jackson D, Whitney CG, Schuchat A, Farley MM, Tenover F, Stephens DS. The emergence of *Streptococcus pneumoniae* resistant to macrolide antimicrobial agents: a 6-year population-based assessment. *J Infect Dis* 2000;182(5):1417-24.

Gherardi G, Whitney CG, Facklam RR, Beall B. Major related sets of antibiotic-resistant pneumococci in the United States as determined by PFGE and *pbp1a-pbp2b-pbp2x-dhf* restriction profiles. *J Infect Dis* 2000;181:216-29.

Harrison LH, Dwyer DM, Billmann L, Kolczak MS, Schuchat A, and the Maryland Emerging Infections Program. Invasive pneumococcal infection in Baltimore: implications for immunization policy. *Arch Intern. Med* 2000;160 (1):89-94.

Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant *Streptococcus pneumoniae* therapeutic working group. *Arch Intern Med* 2000;160:1399-1408.

Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro MJ, Tenover FC. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2000;44:2962-8.

McEllistrem MC, Pass M, Elliott JA, Whitney CG, Harrison LH. Clonal groups of penicillin-nonsusceptible *Streptococcus pneumoniae* in Baltimore, Maryland: A population-based, molecular epidemiologic study. *J Clin Microbiol* 2000;38(12):4367-72.

McEllistrem MC, Stout JE, Harrison LH. Simplified protocol for pulsed-field gel electrophoresis analysis of *Streptococcus pneumoniae*. *J Clin Microbiol* 2000;38:351-3.

Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis* 2000;30:520-8.

Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF, and the Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. *N Engl J Med* 2000;342:681-9.

Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. *Ann Intern Med* 2000;132:182-90.

Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A. Increasing prevalence of multidrug-resistant *Streptococcus pneumoniae* in the United States. *N Engl J Med* 2000;343:1917-24.

1995-1999:

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu99.pdf>

Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in *Streptococcus pneumoniae*- Selected Sites, United States, 1997. *MMWR Morb Mortal Wkly Rep* 1999;48:656-61.

Jacobson T, Thomas D, Morton F, Offutt G, Shevlin J and Ray S. Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates: a randomized controlled trial. *JAMA*. 1999;282:646-50.

Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B for the Active Bacterial Core Surveillance Team. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. *Pediatrics* 1999;103(3):e28.

Beall B, Facklam RR, Jackson DM, Starling HH. Rapid screening of penicillin-susceptibility in systemic pneumococcal isolates by restriction enzyme profiling of the *php 2B* gene. *J Clin Microbiol* 1998;36:2359-62.

Butler JC, Dowell SF, Breiman RF. Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. *Vaccine* 1998;16:1693-7.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu98.pdf>

Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geocoding and linking data from population-based surveillance and the US census to evaluate the impact of median household income on the epidemiology of invasive *Streptococcus pneumoniae* infections. *Am J Epidemiol* 1998;148:1212-8.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu97.pdf>

Centers for Disease Control and Prevention. Assessment of National Reporting of Drug-Resistant *Streptococcus pneumoniae* -- United States, 1995-1996. *MMWR Morb Mortal Wkly Rep* 1996;45:947-59.

Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, Deaver KA, Breiman RF. The prevalence of drug-resistant *Streptococcus pneumoniae* in Atlanta. *N Engl J Med* 1995;333:481-6.

1988-1994:

Schuchat A, Broome CV, Hightower AW, Costa S, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. *JAMA* 1991;265:3275-9.

Other

2000 to present:

Van Beneden C, Olsen S, Skoff T, Lynfield R. Active, population-based surveillance for infectious diseases. In: M'ikanatha NL, R; Van Beneden, CA; de Valk, H, ed. *Infectious Disease Surveillance*. 1st ed: Blackwell Publishers, pp. 32-43, 2007.

Begier EM, Barrett NL, Mshar PA, Johnson DG, Hadler JL, Connecticut Bioterrorism Field Epidemiology Response Team. Gram-positive rod surveillance for early anthrax detection. *Emerg Infect Dis*. 2005;11(9):1483-6.

Pinner RW, Rebmann CA, Schuchat A, Hughes JM. Disease surveillance and the academic, clinical, and public health communities. *Emerg Infect Dis* 2003;9(7):781-7.

Centers for Disease Control and Prevention. HIV testing among pregnant women, United States and Canada, 1998-2001. *MMWR Morb Mortal Wkly Rep* 2002;51(45):1013-6.

Hyde T, Hilger T, Reingold A, Farley MM, O'Brien, Schuchat A. Trends in incidence and antimicrobial resistance of early-onset sepsis: Population-based surveillance in San Francisco and Atlanta. *Pediatrics* 2002;110:690-5.

Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D and Pinner R, for the Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Update from the Active Bacterial Core Surveillance of the Emerging Infections Program Network. *Emerg Infect Dis* 2001;92-9.

Centers for Disease Control and Prevention. Laboratory capacity to detect antimicrobial resistance, 1998. MMWR Morb Mortal Wkly Rep 2000;48(51):1167-71.

1995-1999:

Mead PS, Slutsker L, Dietz V, et al. Food-related Illness and Death in the United States. Emerg Infect Dis 1999;5(5):607-25.